Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ACADEMIA
ACADEMIA
- Obesity Med Wegovy Could Be “Ace in the Hole”, Should Avoid Fate of Oblean: KOL
March 30, 2023
- MHLW Panel OKs Research Report That Could Set Stage for Gene Profiling Before 1st-Line Cancer Therapy
March 15, 2023
- Japan’s Antimicrobial Use in 2022 Levels Off YOY, Down 31.5% from 2013
March 10, 2023
- Probe Panel Recognizes Professor’s COI over Glactiv Scandal, but Doubts Whether It Constitutes Bribery
February 24, 2023
- Investigators Doubt Mitsubishi’s Trial Data on Muse Cell Therapy; Program Aborted without Notice
February 17, 2023
- 80% of Medical Institutions Say Reimbursement Fees “Essential” to Introduce Formularies: Study
February 8, 2023
- Over Half of Pregnant Women Shun COVID Jab for Side Effect Fears: Survey
December 6, 2022
- Lewy Body Dementia Specialist Sees Aricept Approval Modification as Positive Move
December 6, 2022
- Building Delivery Scheme for Disease-Modifying Drugs for Alzheimer’s Is Critical: Academic Societies
November 30, 2022
- Obesity Society to Highlight Proper Use of Semaglutide If Label Expanded
November 29, 2022
- Japan Infectious Diseases Association Updates Guidelines after Xocova Approval
November 25, 2022
- Academic Societies Warn against Hoarding Meropenem as Supply Crunch Intensifies
November 21, 2022
- Japan Pediatric Society Recommends COVID Jab for Ages 4 Years and Younger
November 4, 2022
- Researchers Launch Scientific Society for Oncolytic Virus Therapies
October 31, 2022
- Less than Half of Japan Prefectures Offer SMA Test under Newborn Screening Program: Survey
October 28, 2022
- Japan Expert Sees Lecanemab Initially Treating Only a Few Tens of Thousands of Patients with Immature Care Setup
October 12, 2022
- 3rd COVID-19 Shot for Kids Aged 5-11 Effective as Booster: Infectious Diseases Association
October 5, 2022
- Antimicrobial Use in 2021 Down 31.5% from 2013: Expert
October 5, 2022
- Ivermectin Fails in Investigator-Led COVID Trial Too
October 3, 2022
- Emergency Approval Push for Shionogi’s COVID Pill Not Profit-Driven: Academic Societies
September 9, 2022
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…